AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30095536 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicinumab (100 mg/kg intravenous every 4 weeks for 6 infusions)
Number of subjects: 69
Study 30095536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27654466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative vacuum erection device (VED) use; 10-15 min/day for ≥30 days (Group A)
Number of subjects: 51
Study 27654466 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group B)
Number of subjects: 51
Study 25805530 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mental Health Experience Co‐Design (MH ECO) intervention
Number of subjects: 330
Study 23640743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss (N = 118)
Number of subjects: 439
Study 23640743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (N = 117)
Number of subjects: 439
Study 23640743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (N = 117)
Number of subjects: 439
Study 23640743 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study 21487327 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐HBV‐IPV/Hib
Number of subjects: 780
Study 21487327 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐IPV‐Hib
Number of subjects: 780
Study 21487327 — intervention group
Group type: COMPARATOR
Intervention: 7‐valent pneumococcal conjugate vaccine + DTPa‐IPV‐Hib
Number of subjects: 780
Study 19555810 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg BID)
Number of subjects: 103
Study 19555810 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg BID)
Number of subjects: 103
Study 17588421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest drain
Number of subjects: 60
Study 17588421 — intervention group
Group type: COMPARATOR
Intervention: No chest drain
Number of subjects: 60
Study 15530999 — intervention group
Group type: COMPARATOR
Intervention: Carisoprodol
Number of subjects: 197
Study 15530999 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine hydrochloride
Number of subjects: 197
Study 15530999 — intervention group
Group type: COMPARATOR
Intervention: Metaxalone
Number of subjects: 197
Study 12370851 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in safflower and olive oils
Number of subjects: 21
Study 9824786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg/day for 10 days
Number of subjects: 28
Study 9824786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg/day for 10 days
Number of subjects: 28
Study 9824786 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no rifampicin or rifabutin)
Number of subjects: 28
Study 8131225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance officers at 30 cm H2O
Number of subjects: 0
Study 8131225 — intervention group
Group type: COMPARATOR
Intervention: Ambulance officers at 20 cm H2O
Number of subjects: 0
Study 8131225 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetists with a two-handed grip
Number of subjects: 0
Study 8131225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance officers and anaesthetists
Number of subjects: 0
Study 2509069 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin 300 mg once daily (group A)
Number of subjects: 185
Study 2509069 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin 100 mg three times daily (group B)
Number of subjects: 185
Study 1102329 — intervention group
Group type: EXPERIMENTAL
Intervention: d,1-oxyphedrine (myophedrine)
Number of subjects: 0
Study 1102329 — intervention group
Group type: COMPARATOR
Intervention: 1-oxyphedrine
Number of subjects: 0
Study 31898756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) cheek fillers injection
Number of subjects: 20
Study 31898756 — intervention group
Group type: COMPARATOR
Intervention: Thread lifting for the cheek
Number of subjects: 20
Study 30825454 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 0
Study 30825454 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone
Number of subjects: 0
Study 28109247 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based intervention (IMI) for depression prevention, based on cognitive behavioral therapy (CBT) principles, comprising six weekly modules and two booster sessions.
Number of subjects: 406
Study 28109247 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 406
Study 25418126 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE plus mobile teledermoscopy with detailed SSE instructions
Number of subjects: 58
Study 25418126 — intervention group
Group type: COMPARATOR
Intervention: Clinical skin examination (CSE)
Number of subjects: 58
Study 25418126 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE plus mobile teledermoscopy
Number of subjects: 58
Study 23523432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (gradual sleep extension by advancing bedtimes in the evening)
Number of subjects: 55
Study 23523432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 55
Study 23523432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group
Number of subjects: 55
Study 21125678 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 21125678 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 19424811 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 644
Study 19424811 — intervention group
Group type: COMPARATOR
Intervention: Evidence-based communication
Number of subjects: 644
Study 19424811 — intervention group
Group type: COMPARATOR
Intervention: Patient-based intervention
Number of subjects: 644
Study 19424811 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 644
Study 17265017 — intervention group
Group type: EXPERIMENTAL
Intervention: P-STIM-verum
Number of subjects: 44
Study 17265017 — intervention group
Group type: COMPARATOR
Intervention: P-STIM-placebo
Number of subjects: 44
Study 15243610 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline
Number of subjects: 20
Study 15243610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:100,000 adrenaline
Number of subjects: 20
Study 11552276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass during CABG
Number of subjects: 64
Study 11552276 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass without chronic renal failure (Control)
Number of subjects: 64
Study 11552276 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 64
Study 11552276 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survival
Number of subjects: 64
Study 9572900 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-Targeted Delivery Capsule
Number of subjects: 0
Study 7922092 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (prednisolone, cyclosporin A, azathioprine)
Number of subjects: 492
Study 7922092 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone with cyclosporin
Number of subjects: 492
Study 7922092 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine with prednisolone
Number of subjects: 492
Study 7922092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin, azathioprine, and prednisolone
Number of subjects: 492
Study 7922092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin and prednisolone
Number of subjects: 492
Study 7922092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin, nifedipine, and prednisolone
Number of subjects: 492
Study 3136953 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (27 patients)
Number of subjects: 68
Study 3136953 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance infusion of rt-PA at 0.8 mg/kg during 4 hours (25 patients)
Number of subjects: 68
Study 31713266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG laser treatment
Number of subjects: 23
Study 31713266 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 23
Study 30587761 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day of elemental Mg for three months
Number of subjects: 42
Study 26474452 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 637
Study 26474452 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 637
Study 26474452 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 637
Study 26474452 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 637
Study 22922662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with anterior chamber maintainer and adjustable sutures (technique 1)
Number of subjects: 32
Study 22922662 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with viscoelastic and solely releasable sutures (technique 2)
Number of subjects: 32
Study 23327125 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 0.2 mg/kg
Number of subjects: 8
Study 23327125 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (PLC)
Number of subjects: 8
Study 21265297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived (SD)
Number of subjects: 4
Study 21265297 — intervention group
Group type: EXPERIMENTAL
Intervention: SD + energy deficit
Number of subjects: 4
Study 21265297 — intervention group
Group type: EXPERIMENTAL
Intervention: SD + energy deficit + fluid restricted
Number of subjects: 4
Study 21265297 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 18785308 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 82
Study 18785308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 18785308 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 82
Study 15941886 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (1.8 g/d)
Number of subjects: 29
Study 15941886 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch placebo
Number of subjects: 29
Study 12912695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurement of longest basal diameter
Number of subjects: 644
Study 12912695 — intervention group
Group type: EXPERIMENTAL
Intervention: Echographic measurement of apical height
Number of subjects: 644
Study 12912695 — intervention group
Group type: COMPARATOR
Intervention: Histopathological measurement of longest basal diameter
Number of subjects: 644
Study 12912695 — intervention group
Group type: COMPARATOR
Intervention: Histopathological measurement of apical height
Number of subjects: 644
Study 10622655 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine infusion during the hypothermic period of cardiopulmonary bypass
Number of subjects: 22
Study 10622655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no felodipine infusion)
Number of subjects: 22
Study 8622115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin (8 or 15 mg/kg once daily)
Number of subjects: 1443
Study 8622115 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 1443
Study 8622115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin (7.5 mg/kg twice daily)
Number of subjects: 1443
Study 8622115 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin and Amikacin
Number of subjects: 1443
Study 1827614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 40
Study 1827614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 40
Study 1827614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7028935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 micrograms/kg/minute
Number of subjects: 14
Study 7028935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30268546 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone porous tantalum cage
Number of subjects: 57
Study 30268546 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone graft and plating
Number of subjects: 57
Study 28933613 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered ballroom dancing, 1 hour, twice a week for 10 weeks, led by professional dance teachers.
Number of subjects: 51
Study 28933613 — intervention group
Group type: COMPARATOR
Intervention: Control group received dance class vouchers at the end of the study.
Number of subjects: 51
Study 28933613 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessments of balance, mobility, and function were completed in the home.
Number of subjects: 51
Study 28933613 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test at six months proposed for Phase III trial.
Number of subjects: 51
Study 27253335 — intervention group
Group type: EXPERIMENTAL
Intervention: General Exercise (GE)
Number of subjects: 43
Study 27253335 — intervention group
Group type: COMPARATOR
Intervention: Core Stability Exercise (CSE)
Number of subjects: 43
Study 24836310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1066
Study 24836310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study 21999424 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable laparoscopic trainer
Number of subjects: 29
Study 21999424 — intervention group
Group type: COMPARATOR
Intervention: Standardized laparoscopic trainer
Number of subjects: 29
Study 20575920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group (all non-scrubbed staff wore a mask)
Number of subjects: 827
Study 20575920 — intervention group
Group type: COMPARATOR
Intervention: No Mask group (none of the non-scrubbed staff wore masks)
Number of subjects: 827
Study 20575920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 827
Study 20575920 — intervention group
Group type: COMPARATOR
Intervention: Mask group vs No Mask group
Number of subjects: 827
Study 18270675 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine (0.25 mg/kg BW bolus followed by infusion of 0.06 mg/kg BW/h)
Number of subjects: 80
Study 18270675 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (>3 mg/kg BW/h)
Number of subjects: 80
Study 18270675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16159610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol rich fraction (TRF)
Number of subjects: 19
Study 12548585 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 0
Study 12548585 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 0
Study 10549452 — intervention group
Group type: EXPERIMENTAL
Intervention: Foaming tablet
Number of subjects: 765
Study 10549452 — intervention group
Group type: COMPARATOR
Intervention: Nonoxynol-9 film
Number of subjects: 765
Study 10549452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 765
Study 10549452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both spermicides
Number of subjects: 765
Study 8561056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet (2508‐kJ/d or 600 kcal/d) for 4 weeks
Number of subjects: 14
Study 8561056 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet for 4 weeks (Control)
Number of subjects: 14
Study 8154255 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia with 150 I.U. hyaluronidase (Kinetin) added to 4 mg lidocaine 2% with adrenalin
Number of subjects: 80
Study 8154255 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia without hyaluronidase (Control)
Number of subjects: 80
Study 3537872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurture
Number of subjects: 100
Study 3537872 — intervention group
Group type: COMPARATOR
Intervention: Vitamilk
Number of subjects: 100
Study 30864361 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel (cold steel surgical scalpel №15)
Number of subjects: 80
Study 30864361 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery (electrosurgical microneedle with 0.06mm tip radius, power 12 W)
Number of subjects: 80
Study 30864361 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 80
Study 26797718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative nutritional status assessment
Number of subjects: 100
Study 26797718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative dietary intake
Number of subjects: 100
Study 26797718 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient intake
Number of subjects: 100
Study 24882370 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment combined with consultation with dietician
Number of subjects: 181
Study 24882370 — intervention group
Group type: COMPARATOR
Intervention: Consultations with dietician only
Number of subjects: 181
Study 25138814 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 228
Study 25138814 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 228
Study 21875316 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating (SC) bracket
Number of subjects: 19
Study 21875316 — intervention group
Group type: COMPARATOR
Intervention: Modified twin design (MT) bracket
Number of subjects: 19
Study 19535425 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) for 90 days
Number of subjects: 462
Study 19535425 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) with multivitamins and/or anthelminthics
Number of subjects: 462
Study 19535425 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) with adherence higher than the median
Number of subjects: 462
Study 19535425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daily iron+folic acid
Number of subjects: 462
Study 17595891 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rivaroxaban once, twice or three times daily, or 10, 20 or 30 mg rivaroxaban twice daily
Number of subjects: 0
Study 17595891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban plasma concentrations
Number of subjects: 0
Study 16100502 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 513
Study 12053634 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 12053634 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer mood stabilizers or combinations of mood stabilizers
Number of subjects: 0
Study 9709470 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (0.15 mg/kg/day for months 2, 4, and 6) and steroids (1 g methyl‐prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day for months 1, 3, and 5)
Number of subjects: 32
Study 9709470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5‐2.0 mg/kg/day for 1 year) and steroids in a comparable dose
Number of subjects: 32
Study 8701523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula
Number of subjects: 32
Study 8701523 — intervention group
Group type: COMPARATOR
Intervention: Hudson face mask
Number of subjects: 32
Study 8701523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study 1870651 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory inpatient treatment
Number of subjects: 227
Study 1870651 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory attendance at Alcoholics Anonymous (AA) meetings
Number of subjects: 227
Study 1870651 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of treatment options
Number of subjects: 227
Study 6314140 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.1 microgram per kilogram per minute
Number of subjects: 6
Study 6314140 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol infusion at 0.02 micrograms per kilogram per minute
Number of subjects: 6
Study 6314140 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion at 0.05 micrograms per kilogram per minute after administration of ICI 118551 (2.5 or 5 mg)
Number of subjects: 6
Study 6314140 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion after placebo
Number of subjects: 6
Study 30676772 — intervention group
Group type: EXPERIMENTAL
Intervention: T2* weighted MRI
Number of subjects: 10
Study 30676772 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 weighted MRI
Number of subjects: 10
Study 30676772 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 10
Study 27726259 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed sports therapy (PST) for 6 months
Number of subjects: 64
Study 26916684 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 412
Study 26916684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 20 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 30 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 452
Study 25231896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 21769661 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 50
Study 21769661 — intervention group
Group type: COMPARATOR
Intervention: Combined vertebroplasty with antiresorptive agent
Number of subjects: 50
Study 19111278 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20 mg)
Number of subjects: 31
Study 19111278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31